GenScript Biotech and G42 Healthcare partner to distribute GenScript cPass SARS-CoV-2 neutralisation antibody detection kits. Credit: swiftsciencewriting / Pixabay.

GenScript Biotech’s subsidiary GenScript Biotech Singapore has signed an agreement with UAE’s G42 Healthcare for exploring new solutions to fight against Covid-19.

As part of the deal, the GenScript cPass SARS-CoV-2 neutralisation antibody detection kits will be distributed across 24 locations in the MENA region to assess the effectiveness of vaccines.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

This kit detects neutralising antibodies in individuals without using the live SARS-CoV-2 virus.

The conventional method for the measurement of neutralising antibodies in patient samples needs the use of live cells and a high biosafety level environment (BSL3). The results are obtained after several days.

The new cPass antibody detection kit uses pure proteins and can be performed in most standard laboratories in less than an hour.

GenScript noted that the neutralising antibodies represent the first line of defence against the infection by blocking the virus from binding to the host cells, as a result, inhibiting viral propagation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The cPass kit is said to be the only US FDA Emergency Use Authorized (EUA) serology test for neutralising antibodies from recent and prior infections of the virus.

G42 Healthcare CEO Ashish Koshy said: “Our mission is to provide the definitive, comprehensive and most technologically advanced healthcare solutions in the GCC region.

“Our collaboration with GenScript comes at a time when countries have successfully rolled out national vaccination programs and laboratories can now benefit from rapid detection of the antibodies, thus supporting the healthcare ecosystem.

“Our commitment is to uphold patient health and reinforce our credentials as a trail-blazer in healthcare transformation for the good of all humanity.”